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Summary
Background Little is known about how to scale up care for depression in settings where non-physician lay workers 
constitute the bulk of frontline providers. We aimed to compare a stepped-care intervention package for depression 
with usual care enhanced by use of the WHO Mental Health Gap Action Programme intervention guide (mhGAP-IG).
Methods We did a cluster-randomised trial in primary care clinics in Ibadan, Nigeria. Eligible clinics were those with 
adequate staffing to provide various 24-h clinical services and with regular physician supervision. Clinics (clusters), 
anonymised and stratified by local government area, were randomly allocated (1:1) with a computer-generated random 
number sequence to one of two groups: an intervention group in which patients received a stepped-care intervention 
(eight sessions of individual problem-solving therapy, with an extra two to four sessions if needed) plus enhanced 
usual care, and a control group in which patients received enhanced usual care only. Patients from enrolled clinics 
could participate if they were aged 18 years or older, not pregnant, and had moderate to severe depression 
(scoring ≥11 on the nine-item patient health questionnaire [PHQ-9]). The primary outcome was the proportion 
of patients with remission of depression at 12 months (a score of ≤6 on the PHQ-9, with assessors masked to group 
allocation) in the intention-to-treat population. This trial is registered with the International Standard Randomised 
Controlled Trials Number registry (ISRCTN46754188) and is completed. 
Findings 35 of 97 clinics approached were eligible and agreed to participate, of which 18 were allocated to the 
intervention group and 17 to the control group. 1178 patients (631 [54%] in the intervention group and 547 [46%] in 
the control group) were recruited between Dec 2, 2013, and June 29, 2015, among whom 976 (83%) were female and 
baseline mean PHQ-9 score was 13·7 (SD 2·6). Of the 562 (89%) patients in the intervention group and 473 (86%) in 
the control group who completed 12-month follow-up, similar proportions in each group had remission of depression 
(425 [76%] in the intervention group vs 366 [77%] in the control group; adjusted odds ratio 1∙0 [95% CI 0·70–1·40]). 
At 12 months, 17 (3%) deaths, one (<1%) psychotic illness, and one (<1%) case of bipolar disorder in the intervention 
group, and 16 deaths (3%) and one (<1%) case of bipolar disorder in the control group were recorded. No adverse 
events were judged to be related to the study procedures.
Interpretation For patients with moderate to severe depression receiving care from non-physician primary health-care 
workers in Nigeria, a stepped-care, problem-solving intervention combined with enhanced usual care is similarly 
effective to enhanced usual care alone. Enhancing usual care with mhGAP-IG might provide simple and affordable 
approach to scaling up depression care in sub-Saharan Africa.
Funding UK Medical Research Council.
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 
license.
Introduction
Depression is a substantial cause of disease burden 
globally, including in sub-Saharan Africa.1,2 Studies done 
in Nigeria, which has about one psychiatrist for every 
million people,3 have shown that only around one in five 
people with common mental disorders receive any form 
of treatment and that, even among those with serious 
disorders (including those with suicidal behaviour), only 
around 10% receive minimally adequate treatment.4,5 
Untreated depression can cause disability, reduce quality 
of life, increase risk of suicide, increase health-care use 
and costs, and reduce productivity.6
Several studies have shown the effectiveness of a 
stepped-care approach for treating common mental 
health disorders in primary care in low-income and 
middle-income countries (LMICs).7–9 For example, an 
efficacy trial showed that a psychological intervention 
consisting of six to eight behavioural activation sessions 
delivered by trained lay health workers was, over a 
3-month follow-up period, superior to enhanced usual 
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care among patients in primary care with moderately 
severe to severe depression in India.10 In that study, usual 
care, delivered by physicians, was enhanced with the use 
of the WHO Mental Health Gap Action Programme 
intervention guide (mhGAP-IG)—a guide designed to 
aid non-specialists, especially those working in LMICs, 
in offering evidence-based treatment for common mental 
disorders, including depression. Contextualised to the 
Nigerian health system and pilot-tested,11,12 the guide has 
been adopted by the Nigerian Government for scaling 
up mental health care in the country’s primary care 
settings.13 In another study, among patients in Zimbabwe 
with common mental disorders (mainly depression and 
anxiety), a stepped-care, task-shifting approach in which 
participants received six sessions of problem-solving 
therapy delivered by lay health workers, with the option 
of referral to more experienced clinicians for those 
not improving, was more effective over 6 months than 
enhanced usual care (enhanced by information, edu-
cation, and support to the lay health workers).9 Problem-
solving therapy, a structured but simple psychological 
intervention that has shown some efficacy in depression 
trials,14–16 has been culturally adapted and found to be 
acceptable to both providers and patients with major 
depressive disorder in primary care by our group.17,18 
However, as highlighted in a systematic review, more 
studies are required to provide empirical evidence for 
scalable interventions for depression that can be 
delivered by non-specialist health workers, because 
studies of adequately robust quality are still few.19 More 
studies are especially needed in settings such as those in 
much of sub-Saharan Africa where the bulk of primary 
care services is provided by non-physician, lay health 
workers.
The aim of the STEPCARE study was to evaluate the 
effectiveness and cost effectiveness, over a 12-month 
period, of a structured problem-solving therapy delivered 
within a stepped-care approach by non-physician, lay 
health workers for moderate to severe depression.
Methods
Study design and participants
As described in the protocol,18 the study was a two-arm, 
parallel, cluster-randomised, controlled clinical trial 
conducted in primary care clinics in the city of Ibadan, a 
large metropolis in the southwest of Nigeria. Among all 
the primary health-care centres within the city’s 11 local 
government areas (five urban and six rural), those that 
had a full complement of primary health-care workers (ie, 
adequate staffing to provide a broad range of 24-h clinical 
services and with regular physician super vision) were 
assessed for eligibility. Clinics mainly focused on 
maternal and child health care in the perinatal period 
were excluded. The units of randomisation (clusters) 
Research in context
Evidence before this study
We searched PubMed and PsychINFO from June 1, 2010, 
to June 30, 2012, for evidence relating to the treatment of 
depression in primary care in low-income and middle-income 
countries (LMICs), with no language restrictions. Our search terms 
included “depression” “treatment/interventions”, “primary care” 
“non-physician primary care providers”, “low and middle-income 
countries”, and “lay health workers”. We identified 25 relevant 
papers, and a further eight by hand-searching the references of 
those papers. Evidence suggested that primary care providers can, 
with specialist support, deliver effective interventions for 
depression that include psychological and medication therapies. 
However, although the studies showing effectiveness were done 
in countries classified as LMICs, those countries had much better 
health-care resources than are obtainable in sub-Saharan 
countries. For example, studies done in India and Chile were 
implemented in clinics where routine care was provided by 
physicians. On the contrary, front-line providers in much of 
sub-Saharan Africa, including Nigeria, are non-physician lay 
health workers with much simpler training as health-care 
providers and with very little experience in the provision of 
mental health care. 
Added value of this study
To our knowledge, this is the largest randomised controlled 
trial of the effectiveness and cost-effectiveness of a 
stepped-care intervention for moderate to severe major 
depression consisting of structured problem-solving therapy 
delivered within enhanced routine primary care services in 
sub-Saharan Africa. Usual care was enhanced with WHO’s 
Mental Health Gap Action Programme intervention guide 
(mhGAP-IG) as a clinical support tool. The primary outcome 
was assessed at 12 months after trial entry, thereby decreasing 
the likelihood that the outcomes observed were transient. 
Remission was observed in similar proportions of patients in 
the group that received enhanced usual care alone and in the 
intervention group. 
Implications of all the available evidence
In developing models for integration of mental health care 
into the busy schedule typical of a primary health service, 
there is a need to explore the most feasible and affordable 
pathway to scaling up care for depression in low-resource 
settings. The mhGAP-IG might offer such a prospect by 
providing evidence-based assessment and treatment 
algorithms, including the use of medications, appropriate to 
non-physician primary care workers who are authorised to 
prescribe. Future research should address practical issues 
related to implementing this approach within routine primary 
care, including how to facilitate detection of depression at 
this level of care.
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were primary care clinics, and the units of analysis were 
individual participants. Eligible clinics that provided 
consent to participate were randomly allocated to one of 
two study groups: a stepped care plus enhanced usual 
care group (intervention) or an enhanced usual care only 
group (control).
We recruited consecutive attendees at the enrolled 
clinics who had a score of 11 or higher on the nine-
item patient health questionnaire (PHQ-9),20 which has 
been previously validated in our setting.18,21 Other 
eligibility criteria were ability to speak the study language 
(Yoruba), age 18 years or older, not being pregnant or 
breastfeeding, not needing immediate medical attention, 
and meeting the criteria for a diagnosis of DSM-IV major 
depression assessed with the short form of the composite 
international diagnostic interview.17,22 Full criteria are 
described in the protocol.18
The study was approved by the University of Ibadan and 
University College Hospital ethics committee and was 
monitored by an independent trial steering committee. 
All participants provided written (or witnessed, if illiterate) 
informed consent.
Randomisation and masking
Following recruitment of the initial group of participating 
clinics, anonymised codes for each clinic were provided 
by the research team in Ibadan to the study statistician 
(AAM), who generated the allocation sequence and 
carried out the random allocation. Primary health-care 
centres were stratified by local government area and 
randomly allocated in a 1:1 ratio to the intervention group 
or the control group. For each local government area, 
a single balanced block equal to stratum size was 
generated with use of computer-generated random 
numbers to ensure balanced allocation to treatment 
groups. We aimed to recruit 90 participants from each of 
the 16 clinics initially randomised; however, when 
recruitment was slower than anticipated, we randomised 
an additional 19 clinics. Allocation of these additional 
clinics followed the same procedure.
Outcome assessors were blinded to patients’ group 
allocations, were not involved with screening or 
recruitment of trial participants in the clinic, and were 
randomly assigned to participants from any clinic in 
either group of the study. Data were collected and stored 
electronically using android tablets and downloaded to a 
secure server located in the research office. Data were 
kept anonymously using codes to identify individuals. 
These datasets did not contain the allocation status of the 
participants which was kept as a separate file and was 
available only to the trial statistician.
Procedures
In the Nigerian setting, front-line primary care providers 
consist of nurses, community health officers, and 
community health extension workers, each of whom has 
2–3 years of post-secondary school professional training 
(ie, an average of 14 years’ education). Supervision and 
support to all the primary health-care centres in each 
local government area (typically eight to ten centres) is 
provided by a general practitioner, acting as primary 
health-care coordinator, who runs outpatient clinics, 
provides clinical supervisions on a scheduled regular 
basis across the clinics, responds to clinical emergency 
calls, and has administrative management duties. At 
each of the participating clinics, two front-line primary 
care providers, of any cadre (ie, nurse, community health 
officer, or community health extension worker), were 
selected and trained to provide treatment appropriate to 
the study group.
Providers in the intervention group and the con-
trol group delivered usual care enhanced with the 
mhGAP-IG,23 in which specifications for the treatment of 
depression consist of simple psychosocial approaches, 
including psychoeducation and counselling to address 
stressors and activate social networks, and pharma-
cotherapy when necessary. Primary health-care workers 
in the control group received a 2-day top-up training 
session in the use of mhGAP-IG. Primary health-care 
workers in the intervention group were also trained to 
deliver a structured psychological intervention con-
sisting of behavioural activation (activity scheduling) and 
problem-solving therapy, previously culturally adapted 
and pilot tested by us.17,18 These providers received 6 days 
of training on problem-solving therapy and on use of the 
mhGAP-IG to identify and treat depression, which 
included didactic lectures, clinical demonstrations, role 
plays on the delivery of the manualised intervention, 
procedures for support and supervision by the general 
practitioner through mobile phones, and how to 
monitor patients on antidepressant medication. Trained 
providers had to meet a predefined benchmark for post-
training eval uation to be able to participate in the trial. Of 
the 39 potential providers trained, three did not achieve 
the set of competency standards and were excluded from 
the study. A few months into the trial, two trained 
research supervisors (coordinated by BDO) did a fidelity 
assessment through direct observation and rating of 
a total of 205 randomly selected sessions (around 
six sessions per health worker), using a checklist that 
consisted of key items of the intervention procedures. 
Items were rated as 0 (poor or not done), 1 (fair or 
partially done), or 2 (good or well done).
Consecutive patients at participating primary health-
care centres were screened on the PHQ-9 by trained 
research assistants. Each consenting participant who 
screened positive (scored ≥11 on the PHQ-9) was provided 
with their PHQ-9 score and referred to one of the workers 
providing trial treatment in the clinic.
In the intervention group, in the first step, primary 
health-care workers use participants’ PHQ-9 screen 
scores to determine treatment options: those with scores 
of 11–14 were offered eight sessions of psychological 
intervention delivered by primary health-care workers, 
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and those with scores of 15 or more at baseline were 
assessed for additional antidepressant medication in 
consultation with the supervising general practitioner. 
Therapy sessions were done in person and individually. 
During the first session, participants were offered 
psychoeducation in which information about the 
symptoms of depression, possible causes, and treat-
ments were discussed. After providing reassurance 
about the treatability of their condition, the structure of 
the subsequent sessions was discussed and negotiated. 
The following five sessions dealt with identified 
problems, difficulties, and stressors, with the therapist 
working with the patient to explore potential feasible 
solutions, including how to harness the assistance of 
supportive social networks. In the final two sessions, 
both therapist and patient worked together to integrate 
the experiences of the previous sessions, draw concrete 
lessons, and use these to prepare for the future. After 
the first eight sessions, each participant was reassessed 
with the PHQ-9, this time by the primary health-care 
worker. Those with a PHQ-9 score of 11 or more, or 
greater than 50% of baseline score, proceeded to step 
two. Step two consisted of additional therapy sessions or 
a combination of therapy and medication following a 
review by the supervising physician. All participants 
who did not improve after step two had their cases 
discussed with a psychiatrist in the third (final) step.
In the intervention group, all supervision and 
consultations with doctors were provided on as-needed 
basis and through mobile phone contact, except when a 
face-to-face review was deemed necessary and feasible. 
The components and tasks for each treatment session and 
the clinical decisions and steps were detailed in manuals 
and charts provided to the primary health-care worker and 
the primary care physicians. When medication was 
required, the first-line antidepressant was amitriptyline, 
which non-physician primary care providers in Nigeria are 
authorised to prescribe. The trial manual stipulated that, 
when anti depressant medications were prescribed, the 
frontline clinician consults with the general practitioner 
either face-to-face or via mobile telephone to receive 
appropriate advice on dosing and monitoring. Other 
antidepressants could be prescribed by the general 
practitioners for patients who did not improve or had other 
contraindications to the use of tricyclic antidepressants. 
Any emergent medication side-effects were reviewed in 
consultation with the general practitioner.
Participants in the control group received enhanced 
usual care alone. The choice of intervention (either 
unstructured psychological treatment or medications as 
stipulated in the mhGAP-IG) was at the discretion of the 
primary health-care worker and no specification as to the 
number of sessions was made.
Outcome assessments were done through face-to-face 
interviews at the respondents’ homes. All outcome 
assessors were college-educated, experienced in the 
conduct of surveys, and received 2 weeks of training, 
including trial life interviews, inter-rater exercises, and 
regular field debriefing. Interviewers assessed patients’ 
disability level using the WHO disability assessment 
schedule (WHODAS) 2.0,24 and quality of life using the 
WHO quality-of-life questionnaire (WHOQOL).25 The 
service utilisation questionnaire26 was used to collect 
resource-use data, including any inpatient care, 
consultations with health providers, use of drugs and 
laboratory tests, and time and travel costs associated with 
this service uptake. We obtained information on the 
financing sources for each of the categories to allow for 
an estimation of the extent of private, out-of-pocket 
expenditures incurred by study participants and their 
families. The unit costs or prices of these various 
resource inputs were derived through a costing analysis 
in some participating health facilities with use of data 
collection templates and protocols previously developed 
and applied by us.27 Yoruba versions of all the ques-
tionnaires were derived by standard protocols of iterative 
back-translations, as done in previous surveys, achieving 
good psychometric results.24,28
Costs and cost effectiveness
To assess cost effectiveness at follow-up, changes in service 
costs were analysed with respect to changes on the PHQ-9 
and WHODAS at the 6-month and 12-month follow-up 
visits. The service costs incurred in each group were 
collected with the service utilisation questionnaire. A set of 
unit costs and prices for all inpatient and outpatient service 
use, as well as the costs of the interventions, were generated 
using simplified costing templates and local data inputs. 
Cost-effectiveness acceptability curves were constructed 
for a unit improvement on PHQ-9 and WHODAS.
Outcomes
The primary outcome was the proportion of patients who 
had remission of depression (predefined as PHQ-9 score 
of <6) at 12 months from entry into the trial. Secondary 
outcomes included depression symptoms as a continuous 
PHQ-9 score, assessed at 3 months, 6 months, 9 months, 
and 12 months, as well as level of disability (assessed 
with the WHODAS),24 quality of life (assessed with the 
WHOQOL),25 and health-care use (assessed with the 
service utilisation questionnaire),26 at 6 months and 
12 months. All outcomes were assessed in all enrolled 
patients.
Statistical analysis
Informed by the results of our pilot study,17 we sought to 
detect an absolute difference of 18 percentage points 
(59% in the intervention group and 41% in the control 
group; equivalent odds ratio [OR] 2·1) at 12 months. We 
assumed an intracluster correlation coefficient of 0·05, 
also based on pilot study data, and non-collection of the 
primary outcome for 20% of participants. The uninflated 
sample size required 131 participants per group for 
analysis to detect a difference of 59% versus 41% with 
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80% power and a two-sided α of 5%. We originally aimed 
to recruit 90 individuals per clinic. With 72 participants 
per cluster for analysis and an intracluster correlation 
coefficient of 0·05, the design effect was 4·55, giving a 
total number required for analysis of 1190. We therefore 
aimed to recruit 1440 individuals from 16 clinics. 
However, because participant recruitment was slower 
than anticipated, we recruited and randomised a further 
12 clinics in March, 2014, and seven in November, 2014, 
giving a total of 35 clinics randomised in the study. 
Although the design effect was reduced with an increased 
number of smaller clinics, the total target sample 
remained 1440.
The primary approach for comparative analyses was to 
analyse on an intention-to-treat basis at the individual 
level without imputation of missing data. We used 
descriptive statistics to assess balance between the 
study groups at baseline for both clinic and individual 
participant characteristics. To take appropriate account of 
the hierarchical nature of the data, we used multivariable 
mixed-effects regression models to estimate remission 
from depression at 12 months for the intervention group 
versus the control group. We present unadjusted and 
adjusted estimates. In both analyses, we accounted for 
clustering with use of a mixed-effects model with clinic 
and local government area as random effects. In the 
adjusted estimates, we also adjusted for baseline PHQ-9 
score, age, and primary health-care centre, and for local 
government area as a stratification variable. In a sensitivity 
analysis, we imputed missing primary outcome data 
with multiple imputation. Similar analyses were repeated 
for secondary outcomes. For these secondary continuous 
outcomes, we estimated the difference in mean scores 
between the intervention and control groups. We also 
investigated whether between-group differences varied 
over time by using data from all follow-up visits in 
repeated-measures analyses. We investigated whether 
there was any differential effect of the intervention on 
the primary outcome according to baseline symptom 
severity (PHQ-9 score <16 vs ≥16) by including appropriate 
interaction terms in the primary regression model. 
Because the trial was powered to detect overall differences 
between groups rather than interactions of this kind, 
these results are to be interpreted with caution. For the 
cost and cost-effectiveness analyses, 95% CIs were derived 
through non-parametric bootstrapping techniques owing 
to the non-normal distribution of mean service costs per 
study participant (1000 resamples were run). All analyses 
were done in STATA (version 13.0) software.
This study is registered with the International Standard 
Randomised Controlled Trials Number registry, number 
ISRCTN46754188.
Role of the funding source
The funder of the study had no role in the study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had final respon-
sibility for the decision to submit for publication.
Results
Between Sept 2 and Sept 20, 2013, we approached 
97 of the 186 primary health-care clinics in Ibadan. 
52 of these clinics were ineligible (maternal and child 
health care clinics) and ten declined to participate. The 
Figure: Trial profile
97 primary health care clinics approached and assessed for 
 eligibility
35 clinics eligible and randomly allocated
18 clinics allocated to intervention group (stepped 
 care plus enhanced usual care)
17 clinics allocated to control group (enhanced 
 usual care only)
631 participants eligible and enrolled 547 participants eligible and enrolled
8005 participants screened
 7288 screened negative
   717 with score of ≥11 on PHQ-9 assessed for 
  eligibility
7278 participants screened
 6654 screened negative
   624 with score of ≥11 on PHQ-9 assessed for 
  eligibility
62 clinics excluded
 52 not eligible (maternal and child health-care clinics)
 10 eligible but declined participation 
86 excluded
 56 did not consent
 14 address not found
 10 psychosis
 2 relocated
 2 pregnant 
 2 died
77 excluded
 44 did not consent
 11 address not found
 12 psychosis 
 8 bipolar disorder
 1 relocated 
 1 travelled 
542 completed 6-month assessment 456 completed 6-month assessment
89 did not complete 6-month assessment
 51 not found after repeated visits
 16 relocated
 11 died
 9 did not consent
 1 psychosis 
 1 sick
91 did not complete 6-month assessment
 47 not found after repeated visits
 23 relocated
 9 died
 11 did not consent
 1 bipolar disorder
562 completed 12-month assessment 
 (primary follow-up)
473 completed 12-month assessment 
 (primary follow-up)
69 did not complete 12-month assessment
 20 relocated
 20 not found after repeated visits
 17 died
 9 did not consent 
 1 psychosis
 1 sick
 1 bipolar disorder 
74 did not complete 12-month assessment
 31 relocated
 21 not found after repeated visits
 16 died
 4 did not consent
 1 sick
 1 bipolar disorder
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remaining 35 were randomly allocated: 18 to the 
intervention group and 17 to the control group (figure). 
Recruitment of trial participants started on Dec 2, 2013, 
and ended on June 29, 2015. The last follow-up assessment 
was completed on July 15, 2016. 8005 consecutive patients 
were screened in the intervention group, of whom 
717 (9·0%) screened positive on the PHQ-9, and 
631 (7·9%) were enrolled into the trial. In the control 
group, 624 (8·6%) of 7278 screened patients scored 11 or 
higher on the PHQ-9, and 547 (7·5%) were enrolled into 
the trial (figure). Follow-up at 12 months was completed 
for 562 (89%) of 631 in the intervention group and 
473 (86%) of 547 in the control group. Few patients 
declined participation. The most common reasons for 
attrition in both groups were relocation, non-availability 
after multiple efforts (at least four attempts) were made to 
conduct outcome interviews, and death (figure). No 
demographic or clinical features were associated with 
refusal to participate or with attrition.
Participant characteristics were well balanced between 
the two groups at baseline except for mean age, which was 
higher in the intervention group (table 1). 976 (83%) of 
1178 participants were women. Most participants were 
either unemployed or had unskilled jobs. The mean 
score of 13·7 (SD 2·6) on the PHQ-9 at baseline suggested 
that, across the two groups, most participants had at least 
a moderate severity of depression.
Each session of problem-solving therapy lasted 
30–40 min, with the first session taking slightly longer 
on average (mean 45 min [SD 10]). 183 (89%) of 
205 sessions were rated as substantially adequate in the 
fidelity assessments.
Of the 631 patients who consented to the trial in the 
intervention group, 602 (95%) received at least one 
therapy session, 499 (83%) completed four sessions, and 
476 (79%) completed the eight prescribed sessions in step 
one. Two additional therapy sessions in step two were 
received by 122 (19%) participants. 76 (12%) participants 
in the intervention group were prescribed antidepres-
sant medications (amitriptyline): 70 (11%) commenced 
medication because of severe depression PHQ-9 
score >15) at trial entry, and six (1%) started medication 
following poor response after eight therapy sessions, as 
specified in the protocol. In the control group, 144 (32%) 
of 448 participants for whom complete treatment details 
were available were prescribed amitriptyline. Receipt of 
counselling from other carers (mainly traditional or faith 
healers) was reported by 27 (4%) participants in the 
intervention group and 31 (7%) of 448 in the control 
group. Only two patients were referred to psychiatrists, 
both in the control group.
The groups showed no difference in terms of the 
primary outcome (remission at 12 months: 76% in the 
intervention group vs 77% in the control group; adjusted 
OR 1·0 [95% CI 0·7–1·4]), and this did not change 
when multiple imputation was used to account for 
missing outcome data (table 2). Mean PHQ-9 scores 
were 4·7 (SD 4·5) at 3 months, 3·8 (4·1) at 6 months, 
3·6 (4·2) at 9 months, and 3·6 (4·2) at 12 months for the 
intervention group, and 4·8 (4·2) at 3 months, 4·3 (4·5) 
at 6 months, 3·9 (4·4) at 9 months, and 3·5 (3·9) at 
12 months for the control group. The adjusted mean 
difference in PHQ-9 score (adjusted for baseline PHQ-9 
score and local government area) in the intervention 
group compared with the control group across all follow-
up timepoints was –0·3 (95% CI –0·7 to 0·1, p=0·163).
Secondary outcomes at 6 months and 12 months are 
shown in table 3. In the adjusted analysis, depression 
symptoms were less severe in terms of PHQ-9 score in 
the intervention group than in the control group at 
6 months. Mean psychological quality of life score at 





Age, years 50·2 (15·0) 44·0 (14·5)
Years of education 6·8 (5·4) 7·4 (5·5)
Sex  
Male 104 (16%) 98 (18%)
Female 527 (84%) 449 (82%)
Marital status 
Single 95 (15%) 99 (18%)
Married 486 (77%) 410 (75%)
Separated or divorced 50 (8%) 38 (7%)
Employment status*
Unemployed 66 (10%) 49 (9%)
Housewife 7 (1%) 11 (2%)
Unskilled labourer 387 (61%) 341 (62%)
Skilled labourer 105 (17%) 91 (17%)
Middle-level worker 51 (8%) 30 (5%) 
Professional 6 (1%) 9 (2%)
Unknown 9 (1%) 16 (3%)
PHQ-9 score† 13·7 (2·6) 13·5 (2·6)
WHODAS score‡ 25·4 (9·2) 25·8 (9·6)
WHOQOL scores§
Physical domain 46·6 (21·4) 48·0 (21·9)
Psychological domain 53·6 (20·4) 51·6 (19·6)
Social domain 50·8 (25·6) 49·2 (25·3)
Environmental domain 50·7 (16·4) 47·3 (16·7)
Data are mean (SD) or n (%). PHQ-9=nine-item patient health questionnaire. 
WHODAS=WHO disability assessment schedule. WHOQOL=WHO quality-of-life 
questionnaire. *Employment statuses were defined as follows: unemployed=not 
currently in paid employment; housewife=woman who is a homemaker and not 
seeking employment outside the home; unskilled labourer=worker who has not 
learnt any trade; skilled labourer=artisan; middle-level worker=clerical or 
secretarial staff, junior admin worker, etc; professional=teacher, nurse, doctor, 
senior admin staff, etc. †PHQ-9 scores range from 0 to 27 (nine questions, each 
scored from 0 [best] to 3 [worst]). ‡WHODAS scores range from 12 to 60 
(12 questions each ranging from 1 [best] to 5 [worst], plus three additional 
questions about number of days in the past month the patients has had 
difficulties). §WHOQOL includes 26 questions (with responses ranging from not 
at all or very dissatisfied or very poor, to very much or very good or very satisfied 
or all the time); scores for each domain are transformed to a scale of 0–100, 
with higher scores denoting better quality of life. 
Table 1: Baseline demographic and clinical characteristics
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than in the control group (unadjusted difference 
2·9 [95% CI –0·1 to 5·8]; p=0·058). No differences 
were seen in any other secondary outcome at either 
timepoint.
At 12 months, 17 deaths had occurred in the intervention 
group and 16 in the control group. Information obtained 
from patients’ close relatives and medical records, when 
available, suggested that the causes of death were compli-
cations of hypertension or heart disease (eight [24%] of 
33 patients), tuberculosis (six [18%]), diabetes (two [6%]), 
asthma (two [6%]), liver failure possibly related to 
alcoholism (three [9%]), typhoid fever (two [6%]), and 
cancer (one [3%]). The causes were ascribed to old age or 
were unknown in nine (27%) patients. Only two (6%) of 
the deceased patients were on antidepressant medication 
at the time of death. At the 12-month assessment, 
one (<1%) patient had developed a psychotic illness and 
one (<1%) other had developed bipolar disorder in the 
intervention group, and one (<1%) had developed a 
bipolar disorder in the control group. Suicidal ideation 
was reported by 57 (10%) participants in the intervention 
group and by 66 (14%) of those in the control group. No 
adverse events were judged by the independent trial 
steering committee to be related to the study procedures.
Estimated service costs per participant per month fell 
from 11 392 naira at baseline to 3002 naira (at 6 months) 
and 1729 naira (at 12 months) in the intervention group, 
and from 7254 naira to 1981 naira (at 6 months) and 
further to 1664 naira (at 12 months) in the control group 
(table 4). Over the full 12-month period from baseline, 
the estimated costs per patient were 28 129 naira in the 
stepped-care intervention group and 27 514 naira in 
the control group. Using the 2016 conversion rate of 
150 naira to US$1, these costs translate to $187·50 in 
Remission* at 12 months Unadjusted analysis Adjusted analysis†
Intervention group Control group OR p value OR p value
Non-imputed outcomes 425/562 (76%) 366/473 (77%) 0·9 (0·7–1·2) 0·507 1·0 (0·7–1·4) 0·948
Multiple imputation of missing outcomes 481/631 (76%) 420/547 (77%) ·· ·· 0·95 (0·71–1·29) 0·760
Data are n/N (%) or OR (95% CI). Intracluster correlation coefficient for primary outcome 0·04. OR=odds ratio. PHQ-9=nine-item patient health questionnaire. *Defined as 
PHQ-9 score less than 6. †Adjusted for baseline PHQ-9 score, age, primary health-care centre, and local government area that participants belonged to; primary health-care 
centre and local government area were included as random effects. 
Table 2: Primary analysis and sensitivity analyses
Intervention group Control group Unadjusted analysis Adjusted analysis*
Mean difference p value Mean difference p value
6 months (n=542) (n=456)
PHQ-9 score† 3·8 (4·1) 4·3 (4·5) –0·5 (–1·1 to 0·0) 0·056 –0·7 (–1·3 to –0·2) 0·011
WHODAS score‡ 18·3 (8·8) 19·5 (9·8) –0·9 (–2·7 to 0·9) 0·319 –0·9 (–2·7 to 0·9) 0·314
WHOQOL scores§
Physical domain 67·8 (20·9) 67·2 (22·2) 0·5 (–3·4 to 4·4) 0·794 0·6 (–3·2 to 4·5) 0·747
Psychological domain 61·2 (20·1) 58·1 (21·1) 2·9 (–0·1 to 5·8) 0·058 2·9 (–0.1 to 6.0) 0·061
Social domain 60·3 (19·9) 58·6 (20·7) 2·3 (–0·7 to 5·4) 0·136 2·3 (–0·8 to 5·3) 0·142
Environmental domain§ 57·6 (15·3) 55·0 (16·1) 1·8 (–1·1 to 4·8) 0·224 1·9 (–1·1 to 4·8) 0·214
12 months (n=562) (n=473)
PHQ-9 score† 3·6 (4·9) 3·5 (3·9) 0·1 (–0·4 to 0·6) 0·808 –0·2 (–0·7 to 0·3) 0·398
WHODAS score‡ 17·9 (8·9) 18·5 (9·8) –0·3 (–2·2 to 1·6) 0·729 –0·4 (–2·3 to 1·5) 0·708
WHOQOL scores§
Physical domain 72·7 (20·0) 72·5 (20·3) 0·1 (–2·5 to 2·7) 0·950 0·1 (–2·6 to 2·8) 0·918
Psychological domain 63·9 (20·1) 61·7 (19.6) 2·1 (–0·9 to 5·2) 0·170 2·1 (–0·9 to 5·2) 0·171
Social domain 65·2 (15·9) 64·7 (17·5) 0·5 (–2·0 to 3·0) 0·692 0·5 (–2·0 to 3·0) 0·696
Environmental domain 61·1 (15·4) 59·4 (15·1) 1·5 (–0·8 to 3·8) 0·204 1·5 (–0·8 to 3·8) 0·204
Data are mean (SD) or mean difference (95% CI). PHQ-9=nine-item patient health questionnaire. WHODAS=WHO disability assessment schedule. WHOQOL=WHO quality-of-life 
questionnaire. *Adjusted for baseline PHQ-9 score, primary health-care centre, and local government area that participants belonged to; primary health-care centre and local 
government area were included as random effects. †PHQ-9 scores range from 0 to 27 (nine questions, each scored from 0 [best] to 3 [worst]). ‡WHODAS scores range from 
12 to 60 (12 questions each ranging from 1 [best] to 5 [worst], plus three additional questions about number of days in the past month the patients has had difficulties). 
§WHOQOL includes 26 questions (with responses ranging from not at all or very dissatisfied or very poor, to very much or very good or very satisfied or all the time); scores for 
each domain are transformed to a scale of 0–100, with higher scores denoting better quality of life.
Table 3: Secondary outcomes at 6 months and 12 months
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the intervention group (mean $15·63 per month) and 
$183·40 ($15·28 per month) in the control group.
Over the follow-up period, the stepped-care inter-
vention group showed marginally better symptomatic 
and functional status improvements than those of the 
control group, but considerably greater reductions in 
service costs (table 4). The reduction in cost per one-point 
improvement on the PHQ-9 with the stepped-care 
intervention compared with the control was 4454 naira 
(95% CI –3235 to 13 419) or about $30 at 6 months, 
and 40 727 naira (–12 828 to 102 245) or about $272 at 
12 months. With respect to disability, the reduction in 
cost per one-point improvement on the WHODAS in the 
stepped-care intervention group compared with the 
control group was 3896 naira (–3508 to 12 074) or about 
$26 at 6 months, and 20 364 naira (–6302 to 50 330) or 
about $136 at 12 months (table 4). Although the point 
estimates suggested that the stepped-care intervention 
plus enhanced usual care might be a more cost-effective 
intervention than enhanced usual care alone, there was a 
high degree of uncertainty around these estimates. 
We also produced a  descriptive cost table, scatterplots, 
and acceptability curves, which revealed a probability 
of 55–60% for the intervention being a cost-effective 
approach compared with usual care once a willingness-
to-pay level of 50 000 naira ($333) was reached (appendix).
Discussion
In this study of patients in primary care with major 
depressive disorder of at least moderate severity, the 
proportion of patients with remission of depression at 
12 months was similar among patients who received 
a structured, stepped-care intervention consisting of 
culturally adapted problem-solving therapy and among 
patients who received usual care enhanced with the use of 
mhGAP-IG. Participants in the stepped-care intervention 
group had lower mean PHQ-9 scores at 6 months than 
those in the control group, a difference that is unlikely to 
be clinically important. The stepped-care intervention 
combined with enhanced usual care was found to lower 
costs more than enhanced usual care alone, with some 
evidence for a more favourable cost-effectiveness profile 
for treating depression in this setting. Both groups were 
similar with respect to functional status (as measured 
with the WHODAS 2·0) and health-related quality of life 
(assessed with the WHOQOL-BREF) at the 6-month and 
12-month follow-up visits.
The essential component of the treatment in the 
intervention group was a culturally adapted form of 
problem-solving therapy which, in a pilot study, had been 
shown to be acceptable to both providers and patients. In 
the current study, most participants in the intervention 
group received eight structured sessions of the therapy in 
the first step and a few went on, depending on symptom 
relief, to receive further therapy sessions in the second 
step or were prescribed antidepressants in consultation 
with a physician. On the other hand, participants in 
the control group received a few sessions of basic 
psychosocial treatment, while many more were prescribed 
antidepressants than were those in the inter vention 
group. The two groups of participants had essentially the 
same outcomes.
Few studies in sub-Saharan Africa are available to 
which the results of our study could be compared, the 
most comparable being one conducted in Zimbabwe.9 
Although the follow-up was 6 months in that trial and the 
participants had much milder depression than those in 
the current study (61·8% scored 11 or more on the PHQ-9 
at baseline, compared with 100% in our study), both 
studies compared an intervention consisting of several 
sessions of problem-solving therapy with enhanced usual 
care. The 6-month outcomes in the intervention groups 
of both studies were broadly similar (mean PHQ-9 scores 
4·5 in the Zimbabwe study and 4·3 in our study), whereas 
the outcome of the control group in the current study was 
much better than that of the Zimbabwe study (mean 
PHQ-9 scores 3·8 and 11·0). The enhancement of usual 
care with mhGAP-IG and the associated frequent use of 
antidepressants by the providers in the control group of 
the current trial might be the reason for the differential 
outcome. A 2014 systematic review highlighted the 
importance of assessment and treatment guidelines as 
enablers of successful task-shifting.29 Our observation of 
high and relatively early remission rates is similar to the 
64% remission rate at 3 months in the intervention group 
of the previous trial in India,10 and is consistent with the 
evidence provided by Ilardi and Craighead30 that as much 
as 60–70% of the total improvement achieved through 
cognitive-behavioural treatment for depression occurs in 
the first 4 weeks of therapy.
To our knowledge, our study is the largest in an 
LMIC setting to evaluate the effectiveness and cost 
Baseline 6 months 12 months
Cost analysis
Service cost, naira per participant per month
Intervention group, mean (SD) 11 392 (68 288) 3002 (14 770) 1729 (5864)
Control group, mean (SD) 7254 (28 714) 1981 (7166) 1664 (6616)
Mean difference (95% CI)* ·· 1021 (–211 to 2514) 65 (–766 to 793)
Change in cost since baseline
Intervention group, mean (SE) ·· –8390 (2767) –9663 (2711)
Control group, mean (SE) ·· –5273 (1351) –5590 (1176)
Mean difference (SE) ·· –3117 (3156) –4073 (2923)
Cost-effectiveness analysis
Incremental cost-effectiveness ratio 
(95% CI) based on PHQ-9
·· 4454 
(–3235 to 13 419)
40 727 
(–12 828 to 102 245)
Incremental cost-effectiveness ratio 
(95% CI) based on WHODAS
·· 3896 
(–3508 to 12 704)
20364 
(–6302 to 50 330)
PHQ-9=nine-item patient health questionnaire. WHODAS=WHO disability assessment schedule. *Intervention group 
versus control group, adjusted for baseline costs. 
Table 4: Costs and cost effectiveness of stepped care and enhanced usual care interventions at 6-month 
and 12-month visits
See Online for appendix
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effectiveness of interventions for depression delivered 
by non-physician primary care workers in which follow-
up was over a 12-month period, thus increasing the 
likelihood that the observed outcomes were not 
transient. Trial participants had a rigorously defined 
diagnosis of major depression of at least moderate 
severity, with scores on a validated screening tool 
complemented with a structured diagnostic interview. 
The follow-up rate was high and, with a narrow 95% CI 
in the primary analysis (0·7–1·4) that excluded the effect 
the trial was designed to detect (OR 2·1), there is 
assurance of adequate precision. We used a form of 
problem-solving therapy that had been previously 
culturally adapted and piloted in our setting. Treatments 
were delivered by currently serving primary care 
workers and no new cadres of staff were specially 
recruited. This has the advantage of enhancing appro-
priateness to routine primary care in LMICs, thus 
making sustainability and policy adoption of the 
findings more likely. Outcomes were assessed by 
assessors masked to group allocation, with validated 
tools that had been subjected to cultural adaptation. 
However, given the complex nature of the treatments in 
both groups, it is difficult to be sure about the specific 
aspects of the interventions that were responsible for 
the change in the depression status of the patients. This 
is a common observation in studies exploring complex 
interventions in primary care.9,10,15 For the intervention 
group, although problem-solving therapy has been 
shown to be an effective treatment for depression, the 
frequency of contacts with providers might have been 
important in bringing about remission. In the control 
group, as previously highlighted in a systematic review,29 
the enhancement of usual care by an evidence-based 
assess ment and treatment algorithm that facilitated the 
use of antidepressants by the providers must have been 
of importance, leading to high remission rates. Given 
the similarity in the outcomes in both groups of this 
study, we can infer that the more intensive psychological 
treatment in the intervention group was probably 
counterbalanced by a greater use of anti depressant 
medication in the control group.
The results of this trial should be interpreted with due 
consideration for the limitations. First, about one in 
five eligible clinics declined participation in the trial. 
Second, the intervention was compared with enhanced 
usual care rather than no treatment. This comparison is 
similar to the approach taken in many other studies.9,15 In 
this study, usual care was enhanced with use of an 
evidence-based clinical support tool recently adopted as a 
pathway to scaling up mental health care in the country. 
The participants in the control group thus received more 
intensive care than they would have received before that 
new policy. The observation that as many as 32% of 
patients in the control group received anti depressant 
medication attests to this enhancement. Typically, patients 
with depression would not be prescribed antidepressant 
medications and would receive, when identified, non-
specific counselling, vitamins, or sleep tablets.31,32 A third 
limitation was our inability to detect a difference between 
the two study groups, which might reflect methodological 
issues. For example, although a great majority of the 
providers were rated to have performed well, there was 
still variability in the level of performance. Fourth, the 
much higher proportion of women in the sample, 
although reflecting in part the profile of clinic population 
and the higher occurrence of depression in women, 
might limit the generalisation of findings to men. Fifth, 
we did the fidelity assessment on some but not all therapy 
sessions in the intervention group and none in the control 
group; therefore, we cannot be sure of the adequacy of the 
problem-solving therapy delivery in the non-assessed 
sessions in the intervention group or whether providers 
in the control group also provided sessions that had 
features of problem-solving therapy. The adequacy of the 
assessed sessions in the intervention group might also 
have been partly due to the possibility that providers took 
extra care because of the presence of the assessor.
In summary, for patients presenting with moderate to 
severe depression in primary care settings in sub-
Saharan Africa, a structured problem-solving therapy 
delivered within a stepped-care approach combined with 
usual care (enhanced with use of the WHO mhGAP-IG) 
might provide similar benefit in terms of remission at 
12 months, and might represent a more cost-effective 
intervention compared with enhanced usual care alone. 
Further research is warranted to confirm these findings 
and to elucidate whether, using the mhGAP-IG, non-
physician health workers in routine primary health-care 
settings in LMICs could detect and assess depression 
and offer appropriate treatment.
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